Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 10, 2017 09:00 ET | Source: Fibrocell Science, Inc.

Fibrocell Announces One-for-Three Reverse Stock Split

EXTON, Pa., March 10, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
March 09, 2017 08:00 ET | Source: Fibrocell Science, Inc.

Fibrocell Reports 2016 Financial Results and Recent Operational Highlights

EXTON, Pa., March 09, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
March 07, 2017 17:15 ET | Source: Fibrocell Science, Inc.

Fibrocell to Host Conference Call and Webcast on Thursday, March 9, 2017 to Discuss 2016 Financial Results and Recent Operational Highlights

EXTON, Pa., March 07, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
March 07, 2017 16:54 ET | Source: Fibrocell Science, Inc.

Fibrocell Announces Convertible Preferred Stock Financing for $8.0 Million

EXTON, Pa., March 07, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
February 23, 2017 08:00 ET | Source: Fibrocell Science, Inc.

Fibrocell Announces Dosing of First Patient in Phase I/II Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa

EXTON, Pa., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
January 05, 2017 08:00 ET | Source: Fibrocell Science, Inc.

Fibrocell Announces FDA Fast Track Designation of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa

EXTON, Pa., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
December 19, 2016 08:00 ET | Source: Fibrocell Science, Inc.

Fibrocell Announces Leadership Changes

John Maslowski Succeeds David Pernock as Chief Executive Officer;Douglas Swirsky Appointed Chairman of the Board of Directors EXTON, Pa., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc....
November 10, 2016 08:30 ET | Source: Fibrocell Science, Inc.

Fibrocell Appoints Alfred T. Lane, MD, Chief Medical Advisor

EXTON, Pa., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC) today announced the appointment of Alfred T. Lane, MD, as Chief Medical Advisor of Fibrocell. A board...
November 03, 2016 08:00 ET | Source: Fibrocell Science, Inc.

Fibrocell Reports Third Quarter 2016 Financial Results and Recent Operational Highlights

EXTON, Pa., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC) today reported financial results for the third quarter ended September 30, 2016 and recent operational...
October 31, 2016 16:01 ET | Source: Fibrocell Science, Inc.

Fibrocell to Host Conference Call and Webcast on Thursday, November 3, 2016 to Discuss Third Quarter 2016 Financial Results and Recent Operational Highlights

EXTON, Pa., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC) will report financial results for the third quarter ended September 30, 2016 and recent operational highlights...